Ignite Creation Date:
2025-12-24 @ 5:33 PM
Ignite Modification Date:
2026-05-01 @ 6:10 PM
Study NCT ID:
NCT06932068
Status:
RECRUITING
Last Update Posted:
2025-04-17
First Post:
2025-04-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma
Sponsor:
Qilu Hospital of Shandong University
Organization: